ZELBORAF Drug Patent Profile

Which patents cover Zelboraf, and when can generic versions of Zelboraf launch?

Zelboraf is a drug marketed by Hoffmann La Roche and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and ninety-five patent family members in forty-six countries.

The generic ingredient in ZELBORAF is vemurafenib. One supplier is listed for this compound. Additional details are available on the vemurafenib profile page.

DrugPatentWatch^® Generic Entry Outlook for Zelboraf

Zelboraf was eligible for patent challenges on August 17, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 6, 2032. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for ZELBORAF

International Patents:	195
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	96
Clinical Trials:	53
Patent Applications:	1,764
Drug Prices:	Drug price information for ZELBORAF
What excipients (inactive ingredients) are in ZELBORAF?	ZELBORAF excipients list
DailyMed Link:	ZELBORAF at DailyMed

See drug prices for ZELBORAF

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ZELBORAF

NDA:

202429

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ZELBORAF

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Birmingham	Phase 2/Phase 3
Cancer Research UK	Phase 2/Phase 3
Royal Marsden NHS Foundation Trust	Phase 2/Phase 3

See all ZELBORAF clinical trials

Pharmacology for ZELBORAF

Drug Class	Kinase Inhibitor
Mechanism of Action	Cytochrome P450 1A2 Inhibitors P-Glycoprotein Inhibitors Protein Kinase Inhibitors

US Patents and Regulatory Information for ZELBORAF

ZELBORAF is protected by seven US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes			Y	Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes			Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes			Y	Y
Hoffmann La Roche	ZELBORAF	vemurafenib	TABLET;ORAL	202429-001	Aug 17, 2011		RX	Yes	Yes			Y	Y

EU/EMA Drug Approvals for ZELBORAF

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Roche Registration GmbH	Zelboraf	vemurafenib	EMEA/H/C/002409Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma.,	Authorised	no	no	no	2012-02-17

International Patents for ZELBORAF

When does loss-of-exclusivity occur for ZELBORAF?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

El Salvador

Eurasian Patent Organization

European Patent Office

Honduras

Hong Kong

Hungary

Israel

Japan

Jordan

Malaysia

Mexico

Morocco

New Zealand

Nicaragua

Peru

Poland

Portugal

Russian Federation

San Marino

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZELBORAF around the world.

Country	Patent Number	Title	Estimated Expiration
Croatia	P20151156
Singapore	178208	PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS
Hong Kong	1172906	用於製備藥物活性化合物的方法 (PROCESS FOR THE MANUFACTURE OF PHARMACEUTICALLY ACTIVE COMPOUNDS)
Morocco	33028	تراكيب واستخدامات مرتبطة بها
Denmark	2395004

Supplementary Protection Certificates for ZELBORAF

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1893612	C20120016 00059	Estonia		PRODUCT NAME: ZELBORAF - VEMURAFENIIB;REG NO/DATE: C(2012)1180 FINAL 17.02.2012
1893612	PA2012010	Lithuania		PRODUCT NAME: VEMURAFENIBUM; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
1893612	2012/025	Ireland		PRODUCT NAME: VEMURAFENIB AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/12/751/001 20120217
1893612	12C0040	France		PRODUCT NAME: VEMURAFENIB, EVENTUELLEMENT SOUS LA FORME D'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/12/751/001 20120221
1893612	462	Finland

Market Dynamics and Financial Trajectory for ZELBORAF

Last updated: July 27, 2025

Introduction

ZELBORAF (vemurafenib) represents a pivotal advancement in targeted cancer therapy, specifically designed to treat BRAF V600 mutation-positive melanoma. Since its FDA approval in 2011, ZELBORAF's market performance has been shaped by evolving oncological treatment paradigms, competitive dynamics, regulatory developments, and broader healthcare trends. Analyzing these factors offers insights into its current market standing and future financial trajectory.

Pharmacological Profile and Therapeutic Significance

ZELBORAF functions as a selective inhibitor of the mutated BRAF V600E kinase, which plays a significant role in tumor cell proliferation. Its approval marked an important milestone, offering a targeted approach to metastatic melanoma with BRAF mutations—a subset comprising approximately 50% of melanoma cases [[1]]. The drug’s mechanism of action translated into notable improvements in overall survival (OS) and progression-free survival (PFS), prompting rapid adoption.

The drug's distinct clinical efficacy spurred subsequent approval for other indications, such as BRAF mutation-positive metastatic or unresectable hairy cell leukemia and certain non-small cell lung cancers, fueling expansion into new markets [[2]].

Market Dynamics

Competitive Landscape

ZELBORAF's initial market monopoly was challenged by the emergence of other BRAF inhibitors, most notably PLX8394 (binimetinib) and dabrafenib (Tafinlar), as well as combination therapies like dabrafenib plus trametinib (Mekinist). The combination therapy, approved shortly after ZELBORAF, demonstrated superior efficacy and reduced resistance, becoming the standard of care for many patients [[3]].

Furthermore, immune checkpoint inhibitors such as pembrolizumab (Keytruda) and nivolumab (Opdivo) have become preferred first-line options for melanoma, often relegating BRAF inhibitors to later lines of therapy. The shift towards immunotherapy impacts ZELBORAF’s sales, with a decline observed in monotherapy use but sustained demand in combination or resistant cases.

Regulatory and Patent Considerations

ZELBORAF’s patent life extends into the late 2020s, but evergreening strategies and patent challenges in various jurisdictions could influence its market exclusivity. The introduction of generic versions post-patent expiry will likely lead to significant price erosion, shifting market share dynamics.

Pricing and Reimbursement

The drug's high price point—ranging from $10,000 to $15,000 per month—reflects its targeted mechanism and clinical benefits. Payers have implemented strict reimbursement policies, often favoring combination therapies or immunotherapies due to comparable or superior efficacy at comparable costs [[4]].

Market Penetration and Adoption Trends

ZELBORAF’s adoption varies across geographic regions, with higher penetration in North America and Europe. However, market penetration is constrained by positioning within treatment algorithms favoring immunotherapy and combination regimens. Use of ZELBORAF as monotherapy has declined correspondingly, but it remains an essential therapy for specific patient subsets.

Financial Trajectory

Revenue Trends

Initial sales peaked around 2014–2015, driven by rapid adoption following approval. According to industry reports, ZELBORAF’s peak annual sales exceeded $700 million globally. However, subsequent years saw a gradual decline, attributable to:

• Increased competition from combination therapies and immunotherapies
• Shift in treatment guidelines
• Growing preference for immunotherapy as first-line treatment

Forecasting Future Revenue

Projections indicate a continuing decline in ZELBORAF revenues, especially post-patent expiration around 2026, assuming no new indications or formulations. Nonetheless, niche uses—such as in resistant cases or specific patient populations—notably sustain residual sales.

Innovative formulations (e.g., fixed-dose combinations, improved delivery systems) could mitigate revenue declines if approved. Conversely, advent of newer agents with superior efficacy could accelerate the sales decline, emphasizing the need for strategic positioning and life-cycle management.

Impact of Biosimilars and Generics

The entrance of biosimilars and generics post-patent expiry could significantly reduce ZELBORAF’s market share and pricing, as seen in other targeted therapies. Industry models project potential revenue erosion of up to 70-80% over a 5–7 year period after patent loss, depending on competitive landscape and market receptivity.

Potential for New Indications and Expansion

Ongoing research exploring combination regimens with other targeted agents or immunotherapies may revitalize ZELBORAF’s market share by establishing new treatment indications. Regulatory approval for such combinations could bolster revenue streams.

Strategic Considerations for Stakeholders

• For Manufacturers: Emphasize life-cycle management through label expansion and unique formulations to prolong profitability.
• For Investors: Monitor patent status, competitive pipeline, and emerging therapeutic alternatives.
• For Healthcare Systems: Consider shifting towards immunotherapy-first protocols, potentially limiting ZELBORAF’s role to specific niches.

Conclusion

ZELBORAF's market dynamics reflect a complex interplay of clinical efficacy, competitive innovations, evolving treatment standards, and patent policies. While currently experiencing a revenue decline due to competition and changing treatment paradigms, targeted therapy’s niche role preserves potential for sustained, albeit reduced, financial contributions. Strategic lifecycle management and adaptation to the evolving oncology landscape will be crucial for maximizing ZELBORAF’s financial trajectory.

---

Key Takeaways

• ZELBORAF pioneered targeted therapy for BRAF V600E melanoma but faces diminishing market share due to immunotherapies and combination regimens.
• Revenue peaked in the mid-2010s but has declined, with future sales heavily contingent on patent expiration and competitive developments.
• Industry forecasts predict significant revenue erosion post-patent, emphasizing the importance of innovation and diversification strategies.
• Incorporation of new indications and combination therapies could mitigate decline risks and foster revenue recapture.
• Stakeholders should closely monitor regulatory developments, patent statuses, and emergent competitors to optimize strategic planning.

---

FAQs

Q1: When is ZELBORAF’s patent expected to expire, and how will it impact sales?
A: Patent protection for ZELBORAF is anticipated to expire around 2026. Post-expiry, biosimilar versions are expected to enter the market, likely causing substantial price erosion and a decline in sales.

Q2: How does ZELBORAF compare with recent combination therapies in terms of efficacy?
A: Combination regimens like dabrafenib plus trametinib demonstrate superior efficacy and durability compared to ZELBORAF monotherapy, leading to their preference in standard treatment guidelines.

Q3: Are there ongoing efforts to repurpose ZELBORAF or expand its indications?
A: Yes, research explores ZELBORAF's potential in non-melanoma cancers with BRAF mutations, aiming to broaden its therapeutic scope and sustain revenues.

Q4: What role does ZELBORAF play in current melanoma treatment algorithms?
A: ZELBORAF remains a treatment option primarily for patients with BRAF V600 mutations, often in cases where immunotherapy is unsuitable or has failed, but is increasingly supplanted by combination therapies and immunotherapy as first-line treatments.

Q5: How might innovative formulations affect ZELBORAF’s future market?
A: Improved formulations or delivery methods could enhance efficacy, adherence, or safety, offering opportunities to extend market relevance and revenues.

---

References

[1] American Cancer Society. Melanoma Treatment. 2022.
[2] FDA. ZELBORAF (vemurafenib) Label. 2011.
[3] Oncology Reports. Comparative efficacy of BRAF inhibitors. 2020.
[4] IQVIA. Oncology drug market review, 2021.